Target Information

Target General Infomation
Target ID
T17687
Former ID
TTDR00314
Target Name
Fibroblast growth factor receptor
Synonyms
FGF receptor
Target Type
Clinical Trial
Disease Cancer [ICD9: 140-229; ICD10: C00-C96]
Late-stage solid tumors [ICD9: 140-199, 210-229; ICD10: C00-C75, C7A, C7B, D10-D36, D3A]
Multiple myeloma [ICD9: 203; ICD10: C90]
Drugs and Mode of Action
Drug(s) PD173074 Drug Info Phase 2 Discovery agent [468136], [523642]
TAS-120 Drug Info Phase 1/2 Multiple myeloma [524629]
BAY1163877 Drug Info Phase 1 Cancer [524506]
Debio 1347 Drug Info Phase 1 Late-stage solid tumors [549439]
PD166866 Drug Info Terminated Discovery agent [546718]
Modulator ARO 087 Drug Info [549700]
Debio 1347 Drug Info [532934]
Antagonist BAY1163877 Drug Info [549768]
PD166866 Drug Info [535271]
PD173074 Drug Info [535271]
SU4984 Drug Info [535271]
SU5403 Drug Info [535271]
TAS-120 Drug Info [549968]
References
Ref 468136(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5037).
Ref 523642ClinicalTrials.gov (NCT01441297) BIBF 1120 as Second Line Treatment for Small Cell Lung Cancer. U.S. National Institutes of Health.
Ref 524506ClinicalTrials.gov (NCT01976741) Phase I Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor. U.S. National Institutes of Health.
Ref 524629ClinicalTrials.gov (NCT02052778) A Dose Finding Study Followed by a Safety and Efficacy Study in Patients With Advanced Solid Tumors or Multiple Myeloma With FGF/FGFR-Related Abnormalities. U.S. National Institutes of Health.
Ref 546718Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009865)
Ref 549439Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800037338)
Ref 532934The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor. Mol Cancer Ther. 2014 Nov;13(11):2547-58.
Ref 535271Tumor angiogenesis as a therapeutic target. Drug Discov Today. 2001 Oct 1;6(19):1005-1024.
Ref 549700J Clin Oncol 33, 2015 (suppl; abstr 2545).
Ref 549768Preclinical profile of BAY 1163877 - a selective pan-FGFR inhibitor in phase 1 clinical trial. Cancer Research. 10/2014; 74(19 Supplement):1739-1739.
Ref 549968TAS-120, a highly potent and selective irreversible FGFR inhibitor, is effective in tumors harboring various FGFR gene abnormalities. Molecular Cancer Therapeutics. 01/2014; 12(11_Supplement):A270-A270.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.